16733-90-7

Usage

Uses

Used in Pharmaceutical Industry:
THIAZOLE-2-CARBOXYLIC ACID HYDRAZIDE is used as a potential anti-tuberculosis agent for its ability to target and combat tuberculosis-causing bacteria. Its unique structure and properties make it a candidate for the development of new treatments against drug-resistant strains of tuberculosis.
Used in Organic Synthesis:
In the field of organic synthesis, THIAZOLE-2-CARBOXYLIC ACID HYDRAZIDE serves as a versatile reagent, facilitating the creation of a variety of complex organic compounds. Its carboxylic acid functional group allows for a range of chemical reactions, making it a valuable component in the synthesis of heterocyclic compounds and other organic molecules.
Used in Antimicrobial and Antifungal Applications:
THIAZOLE-2-CARBOXYLIC ACID HYDRAZIDE is utilized as an antimicrobial and antifungal agent, leveraging its chemical properties to inhibit the growth of various microorganisms. This makes it a potential candidate for use in the development of new antimicrobial drugs and treatments for fungal infections.
Used in Research and Development:
In the realm of research and development, THIAZOLE-2-CARBOXYLIC ACID HYDRAZIDE is employed as a building block for the creation of novel chemical entities. Its unique structure and reactivity contribute to the advancement of chemical research, potentially leading to the discovery of new pharmaceuticals and other applications in various industries.

InChI:InChI=1/C4H5N3OS/c5-7-3(8)4-6-1-2-9-4/h1-2H,5H2,(H,7,8)

Upstream product

• 14527-42-5 thiazole-2-carboxylic acid ethyl ester 
• 1254073-54-5 1,1-dimethylethyl 2-(1,3-thiazol-2-ylcarbonyl)hydrazinecarboxylate 

Downstream Products

• 1254073-10-3 7-[(2,3-dichlorophenyl)carbonyl]-3-(1,3-thiazol-2-yl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine 
• 1254073-18-1 7-[(3-chloro-4-fluoro-2-methylphenyl)carbonyl]-3-(1,3-thiazol-2-yl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine 
• 1254073-13-6 7-[(2,4-dichlorophenyl)carbonyl]-3-(1,3-thiazol-2-yl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine 
• 1254073-16-9 7-[(3-chloro-2-methylphenyl)carbonyl]-3-(1,3-thiazol-2-yl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine 
• 1375182-32-3 C₁₅H₁₀FN₅S₂ 
• 16733-85-0 thiazole-2-carboxamide 

Relevant academic research and scientific papers

Discovery of Novel Triazolothiadiazines as Fungicidal Leads Targeting Pyruvate Kinase

Pyruvate kinase (PK) was discovered as a potent new target for novel fungicide development. A series of novel triazolothiadiazine derivatives were rationally designed and synthesized by a ring expansion strategy and computer-aided pesticide design using the 3D structure of Rhizoctonia solani PK (RsPK) obtained by homology modeling as a receptor and our previously discovered lead YZK-C22 as a ligand. The in vitro bioassay results indicated that compounds 4g, 6h, 6m, 6n, 6o, and 6p exhibited good activity against R. solani with the EC50 values falling between 10.99 and 72.76 μM. Especially, 6m showed similar potency to YZK-C22 (10.99 vs 11.97 μM of the EC50 value, respectively). The in vivo bioassay results suggested that 6m against R. solani at a concentration of 200 μg/mL displayed a numerically higher inhibition than YZK-C22 (70 vs 60%, respectively). A field experiment validated that 6m at an application rate of 120 g ai/ha showed comparable efficacy against R. solani to thifluzamide at an application rate of 80 g ai/ha (77.80 vs 84.5%, respectively). Enzymatic inhibition suggested that the potency of 6m was about twofold lower than that of YZK-C22 (67.30 vs 32.64 μM of IC50, respectively). Fluorescence quenching studies validated that RsPK was quenched by both 6m and YZK-C22, implying that they both might act at the same target site of PK. A possible binding conformation of 6m in the RsPK active site was depicted by molecular docking. Our studies suggest that 6m could be a fungicidal lead targeting PK.

PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST

Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as an A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an A2A receptor antagonist.

Compounds Which Selectively Modulate The CB2 Receptor

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6 R7, optionally substituted heteroaryl (Het), or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis or neurodegenerative disorders.